Top

Published in:

01-08-2015 | Research Article

Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression

Authors: Fan Yang, Jian Wang, Hua-yan Ren, Juan Jin, Ai-lian Wang, Li-li Sun, Ke-xin Diao, En-hua Wang, Xiao-yi Mi

Published in: Tumor Biology | Issue 8/2015

Abstract

In this study, we examined protein arginine methyltransferase 5 (PRMT5) and tumor necrosis factor receptor-associated 4 (TRAF4) expression in breast cancer to find the interaction mechanism between the two. We examined TRAF4 and PRMT5 expression by immunohistochemistry and found that their expression is positively correlated in breast cancer. Besides, PRMT5 expression was significantly associated with histological type and tumor size (p < 0.05). PRMT5 nuclear expression was significantly associated with HER2 expression (p < 0.05). PRMT5 and TRAF4 were both overexpressed in breast cancer tissues and cells, and we found that PRMT5 binds to the zinc finger structures in TRAF4 by coimmunoprecipitation and Western blotting. We also tested the potential regulatory effect between TRAF4 and PRMT5. TRAF4 upregulated PRMT5 expression, which occurred predominantly in the nucleus, on which TRAF4 promotion of cell proliferation in breast cancer is mainly dependent. PRMT5 may play an important role in activation of the NF-κB signaling pathway.

Available only for authorised users

Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 2001;13:389–400.CrossRefPubMed

Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115(Pt4):679–88.PubMed

Mathew SJ, Rembold M, Leptin M. Role for Traf4 in polarizing adherens junctions as a prerequisite for efficient cell shape changes. Mol Cell Biol. 2011;31:4978–93.CrossRefPubMedPubMedCentral

Mathew SJ, Kerridge S, Leptin M. A small genomic region containing several loci required for gastrulation in Drosophila. PLoS ONE. 2009;4:e7437.CrossRefPubMedPubMedCentral

Kalkan T, Iwasaki Y, Park CY, Thomsen GH. Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor-beta signaling that affects neural crest formation. Mol Biol Cell. 2009;20:3436–50.CrossRefPubMedPubMedCentral

Ahmed F, Shiraishi T, Vessella RL, Kulkarni P. Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep. 2013;30(6):2963–8.PubMed

Kedinger V, Rio MC. TRAF4, the unique family member. Adv Exp Med Biol. 2007;597:60–71.CrossRefPubMed

Regnier CH, Tomasetto C, Moog-Lutz C, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 1995;270(43):25715–21.CrossRefPubMed

Zapata JM, Matsuzawa S, Godzick A, Leo E, Wasserman SA, Reed JC. The drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with pelle and regulates NFkappaB activity. J Biol Chem. 2000;275(16):12102–7.CrossRefPubMed

10.

Kuranaga E, Kanuka H, Igaki T, et al. Reaper-mediated inhibition of DIAPl-induced DTRAF1 degradation results in activation of JNK in Drosophila. Nat Cell Biol. 2002;4(9):705–10.CrossRefPubMed

11.

Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25(6):2320–30.CrossRefPubMedPubMedCentral

12.

Bedford MT. Arginine methylation at a glance. J Cell Sci. 2007;120(24):4243–6.CrossRefPubMed

13.

Ren J, Wang Y, Liang Y, Zhang Y, Bao S, Xu Z. Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis. J Biol Chem. 2010;285(17):12695–705.CrossRefPubMedPubMedCentral

14.

Zhou Z, Sun X, Zou Z, et al. PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130. Cell Res. 2010;20(9):1023–33.CrossRefPubMed

15.

Dacwag CS, Bedford MT, Sif S, Imbalzano AN. Distinct protein arginine methyltransferases promote ATP-dependent chromatin remodeling function at different stages of skeletal muscle differentiation. Mol Cell Biol. 2009;29(7):1909–21.CrossRefPubMedPubMedCentral

16.

Mallappa C, Hu YJ, Shamulailatpam P, Tae S, Sif S, Imbalzano AN. The expression of myogenic microRNAs indirectly requires protein arginine methyltransferase (Prmt)5 but directly requires Prmt4. Nucleic Acids Res. 2011;39(4):1243–55.CrossRefPubMed

17.

Eckert D, Biermann K, Nettersheim D, et al. Expression of BLIMP1/PRMT5 and concurrent histone H2A/H4 arginine 3 dimethylation in fetal germ cells, CIS/ IGCNU and germ cell tumors. BMC Dev Biol. 2008;8:106.CrossRefPubMedPubMedCentral

18.

Tanaka H, Hoshikawa Y, Oh-hara T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res. 2009;7(4):557–69.CrossRefPubMed

19.

Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. Plos One. 2012;7(8):e44033.CrossRefPubMedPubMedCentral

20.

Nicholas C, Yang J, Peters SB, et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27 (Kip1.). Plos One. 2013;8(9):e74710.CrossRefPubMedPubMedCentral

21.

Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013;61(3):206–17.CrossRefPubMedPubMedCentral

22.

Rozan LM, El-Deiry WS. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biol Ther. 2006;5(9):1228–35.CrossRefPubMed

23.

Zhang X, Wen Z, Sun L, et al. TRAF2 regulates the cytoplasmic/nuclear distribution of TRAF4 and its biological function in breast cancer cells. Biochem Biophys Res Commun. 2013;436(2):344–8.CrossRefPubMed

24.

Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE. Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation. J Biol Chem. 2014;289(22):15328–39.CrossRefPubMedPubMedCentral

25.

Wei H, Wang B, Miyagi M, et al. PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci U S A. 2013;110(33):13516–21.CrossRefPubMedPubMedCentral

26.

Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011;71(16):5579–87.CrossRefPubMedPubMedCentral

27.

Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598–607.CrossRefPubMed

28.

Salmon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.CrossRef

29.

Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002;62(3):652–5.PubMed

30.

Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappa B (NF-kappa B) signaling in breast cancer. J Cell Physiol. 2006;209(3):645–52.CrossRefPubMed

Title: Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression
Authors: Fan Yang
Jian Wang
Hua-yan Ren
Juan Jin
Ai-lian Wang
Li-li Sun
Ke-xin Diao
En-hua Wang
Xiao-yi Mi
Publication date: 01-08-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3262-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells

Thermo-chemotherapy Induced miR-218 upregulation inhibits the invasion of gastric cancer via targeting Gli2 and E-cadherin

Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer

Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress

Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy

Genetic dissimilarity between primary colorectal carcinomas and their lymph node metastases: ploidy, p53, bcl-2, and c-myc expression—a pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer